Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer

References

• JemalASiegelRWardEHaoYXuJThunMJCancer Statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• HamiltonAHortobagyiGChemotherapy: what progress in the last 5 years?J Clin Oncol20052381760177515755984
   PubMed Web of Science ®Google Scholar
• BollagDMMcQueneyPAZhuJEpothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of actionCancer Res19955511232523337757983
   PubMed Web of Science ®Google Scholar
• GerthKBedorfNHofleGIrschikHReichenbachHEpothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological propertiesJ Antibiot (Tokyo)19964965605638698639
   PubMed Web of Science ®Google Scholar
• LeeFYBorzilleriRFairchildCRBMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacyClin Cancer Res2001751429143711350914
   PubMed Web of Science ®Google Scholar
• LeeFYBorzilleriRFairchildCRPreclinical discovery of ixabepilone, a highly active antineoplastic agentCancer Chemother Pharmacol200863115716618347795
   PubMed Web of Science ®Google Scholar
• Boehnke MichaudLThe optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancerJ Oncol Pharm Pract20091529510619171553
   PubMedGoogle Scholar
• NettlesJHLiHCornettBKrahnJMSnyderJPDowningKHThe binding mode of epothilone A on alpha,beta-tubulin by electron crystallographyScience2004305568586686915297674
   PubMed Web of Science ®Google Scholar
• LeeFYSmyklaRJohnstonKPreclinical efficacy spectrum and pharmacokinetics of ixabepiloneCancer Chemother Pharmacol200963220121218350296
   PubMed Web of Science ®Google Scholar
• DumontetCJordanMALeeFFIxabepilone: targeting betaIII-tubulin expression in taxane-resistant malignanciesMol Cancer Ther200981172519139109
   PubMed Web of Science ®Google Scholar
• RiveraELeeJDaviesAClinical development of ixabepilone and other epothilones in patients with advanced solid tumorsOncologist200813121207122319088324
   PubMed Web of Science ®Google Scholar
• AwadaAPiccartMJJonesSFPhase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyCancer Chemother Pharmacol200963341742518446338
   PubMed Web of Science ®Google Scholar
• ManiSMcDaidHHamiltonAPhase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsClin Cancer Res20041041289129814977827
   PubMed Web of Science ®Google Scholar
• GadgeelSMWozniakABoinpallyRRPhase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B designClin Cancer Res200511176233623916144926
   PubMed Web of Science ®Google Scholar
• ShimizuTYamamotoNYamadaYPhase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumorsCancer Chemother Pharmacol200861575175817594093
   PubMed Web of Science ®Google Scholar
• AghajanianCBurrisHA3rdJonesSPhase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasJ Clin Oncol20072591082108817261851
   PubMed Web of Science ®Google Scholar
• ZhuangSHAgrawalMEdgerlyMA phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysCancer200510391932193815800893
   PubMed Web of Science ®Google Scholar
• AbrahamJAgrawalMBakkeSPhase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJ Clin Oncol20032191866187312721265
   PubMed Web of Science ®Google Scholar
• DelfinoCCacciaGGonzalesLRGemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancerOncology2004661182315031594
   PubMed Web of Science ®Google Scholar
• DemirayMKurtEEvrenselTPhase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposureCancer Invest200523538639116193637
   PubMed Web of Science ®Google Scholar
• HensleyMLDizonDDerosaFA phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsInvest New Drugs200725433534117364235
   PubMed Web of Science ®Google Scholar
• PlummerRWollPFyfeDA phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesClin Cancer Res200814248288829419088046
   PubMed Web of Science ®Google Scholar
• GoelSCohenMComezogluSNThe effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical developmentClin Cancer Res20081492701270918451235
   PubMed Web of Science ®Google Scholar
• Ixempra (ixabepilone) intravenous infusion package insertSquibbBMPrinceton, NJBristol-Myers Squibb
   Google Scholar
• PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol200725233407341417606974
   PubMed Web of Science ®Google Scholar
• OnitiloAAEngelJMGreenleeRTMukeshBNBreast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survivalClin Med Res200971–241319574486
   PubMedGoogle Scholar
• TalbotDCMoiseyenkoVVan BelleSRandomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesBr J Cancer20028691367137211986765
   PubMed Web of Science ®Google Scholar
• PerezEAPaclitaxel in breast cancerOncologist19983637338910388129
   PubMedGoogle Scholar
• BonneterreJSpielmanMGuastallaJPEfficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experienceEur J Cancer199935101431143910673974
   PubMed Web of Science ®Google Scholar
• TrudeauMEPhase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancerSemin Oncol1999263Suppl 8212610403470
   PubMed Web of Science ®Google Scholar
• DegardinMBonneterreJHecquetBVinorelbine (navelbine) as a salvage treatment for advanced breast cancerAnn Oncol1994554234268075049
   PubMed Web of Science ®Google Scholar
• IbrahimNKRahmanZValeroVPhase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinomaCancer19998671251125710506711
   PubMed Web of Science ®Google Scholar
• ThomasETaberneroJFornierMPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerJ Clin Oncol200725233399340617606975
   PubMed Web of Science ®Google Scholar
• DenduluriNLowJALeeJJPhase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesJ Clin Oncol200725233421342717606971
   PubMed Web of Science ®Google Scholar
• RocheHYelleLCognettiFPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyJ Clin Oncol200725233415342017606972
   PubMed Web of Science ®Google Scholar
• MillerKDE2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancerClin Breast Cancer20033642142212636887
   PubMedGoogle Scholar
• GrayRBhattacharyaSBowdenCMillerKComisRLIndependent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancerJ Clin Oncol200927304966497219720913
   PubMed Web of Science ®Google Scholar
• CarverLASchnitzerJECaveolae: mining little caves for new cancer targetsNat Rev Cancer20033857158112894245
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
   PubMed Web of Science ®Google Scholar
• BunnellCVahdatLSchwartzbergLPhase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancerClin Breast Cancer20088323424118650153
   PubMed Web of Science ®Google Scholar
• ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol200725335210521717968020
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• ThomasESIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol20082613222318445853
   PubMed Web of Science ®Google Scholar
• BaselgaJZambettiMLlombart-CussacAPhase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJ Clin Oncol200927452653419075286
   PubMed Web of Science ®Google Scholar
• LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol200624101633164216575015
   PubMed Web of Science ®Google Scholar
• RugoHLyssAMoreno AspitiaAPhase III randomized study of paclitaxel versus paclitaxel albumin-stabilized nanoparticle formulation versus ixabepilone in combination with bevacizumab in patients with locally recurrent, stage IIIB or IV breast cancer2008 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=617539&version=HealthProfessional&protocolsearchid=7150845#Objectives_CDR0000617539Accessed October 20, 2009
   Google Scholar
• SchwartzbergLSTrial of dasatinib plus ixabepilone in 2nd or 3rd line metastatic breast cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=647959&version=HealthProfessional&protocolsearchid=7150845Accessed October 20, 2009
   Google Scholar
• YardleyDAPhase I/II Trial of sorafenib plus ixabepilone in Her2-negative metastatic breast cancer2009 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=633738&version=HealthProfessional&protocolsearchid=7150845Accessed October 20, 2009
   Google Scholar
• Karantza-WadsworthVPhase I/II study of ixabepilone and hydroxychloroquine in patients with taxane- and anthracycline-resistant metastatic breast cancer2008 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=615000&version=HealthProfessional&protocolsearchid=7150845#ContactInfo_CDR0000615000Accessed October 20, 2009
   Google Scholar